Stock Detail
EURAND NV - ORDINARY SHARES
EURX @ Yahoo Finance | EURX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $11.99 | $11.99 | $0.00 | 0.00% | 0.00 | $11.99 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.00 | 0 | 573.66M | 475,307 | -85.61 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 19.98 | 15.98 | 7.99 | 3.99 | -4.00 |
Stock Profile
Eurand N.V., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Its lead product candidate includes EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency. The company's product pipeline also comprises EUR-1047, an over-the-counter allergy medication; EUR-1002, which is a formulation of cyclobenzaprine for muscle relaxation; and EUR-1000 a formulation of propranolol for the treatment of hypertension and migraines. Its proprietary drug formulation technologies include customized release technologies to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; dosage form technologies to increase patient compliance through convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technology to improve drug absorption, resulting in dose reduction, and improved onset of action; and drug conjugation technology to extend drug half-life and to target specific organs or other biological targets, such as tumors. The company, formerly known as Eurand B.V., was incorporated in 1984 and is based in Amsterdam, the Netherlands.